'EPSRC and SFI Centre for Doctoral Training in Engineered Tissues for Discovery, Industry and Medicine

lifETIME CDT将重点发展非动物技术（NATs），用于药物开发、毒理学和再生医学。工业生命科学部门占所有商业研发支出的22%，在英国产生640亿英镑的营业额，预计未来十年将以每年10%的速度增长。来自多个来源的分析[1,2]强调了技能短缺给该行业带来的限制，特别是在工程和物理科学领域。我们成功地吸引了付费合作伙伴，投资于以NATs形式提供下一代药物开发、毒理学和再生医学（先进治疗药物产品，ATMP）解决方案的技能培训，这表明英国在这一增长领域的需求。CDT是及时的，因为它不仅是需要发展的科学，而且是整个NAT生态系统-科学，制造，法规，政策和传播。因此，需要建立一个由熟练的领域领导者组成的相互联系的社区的CDT模式，以促进英国在该领域的经济增长。我们的利益相关者合作伙伴和行业俱乐部已经同意帮助我们提供实现我们目标所需的培训。他们的意愿再次证明了该行业对我们毕业生的需求。这个CDT的培训将涉及优先领域7——“生物经济工程”的所有方面。具体而言，我们将：(1)提供与行业合作开发并与行业相关的培训。-我们与来自生物材料、细胞制造、合同研究组织和制药行业的工业伙伴合作，以满足行业需求。(2)促进多学科工程和物理科学培训，使学生能够利用新出现的机会。-我们建立了一个多学科的管理团队，他们的背景包括生物工程、细胞工程、芯片技术、物理学、电子工程、基因组技术、生命科学、临床科学、再生医学和制造业；队列社区将分享这种多学科。每个学生将有一门物理科学、一门生物医学和一名利益相关者导师，再次加强了多学科性。(3)解决与药品生产相关的关键挑战。-我们将通过积极参与药物筛选的制药和cro的利益相关者参与解决药品生产挑战，包括阿斯特拉利康、查尔斯河实验室、Cyprotex、LGC、日产化学、Reprocell、syature Discovery和天津。(4)在产品放大和工艺开发中嵌入创新方法。-我们将通过与合作伙伴密切合作，包括过程创新中心、细胞和基因治疗Catapult以及向市场提供NATs的工业合作伙伴（如Cytochroma、InSphero和OxSyBio），来嵌入这些方法。(5)确保学生理解负责任的研究与创新（RRI）、数据问题、卫生经济学、监管问题和用户参与策略。-为了确保学生了解RRI、数据问题、经济学、监管问题和用户参与策略，我们与企业家商学院合作开展了专业技能培训，提供经济学和企业家精神，使用TERRAIN进行RRI，与nc3r、SNBTS和MHRA的链接，以帮助进行监管培训，并让利益相关者合作伙伴作为一个整体参与进来，以帮助用户参与。制药、UKRI和工业界的统计数据，以及我们的利益相关者参与CDT的意愿，为该行业对高技能毕业生的需求提供了充分的证据。我们的培训是量身定制的，以提供这些毕业生，并建立一个具有发达的科学，专业和RRI技能的包容，有凝聚力的社区。[1] https://goo.gl/qNMTTD[2] https://goo.gl/J9u9eQ

The lifETIME CDT will focus on the development of non-animal technologies (NATs) for use in drug development, toxicology and regenerative medicine.The industrial life sciences sector accounts for 22% of all business R&D spend and generates £64B turnover within the UK with growth expected at 10% pa over the next decade. Analysis from multiple sources [1,2] have highlighted the limitations imposed on the sector by skills shortages, particularly in the engineering and physical sciences area.Our success in attracting pay-in partners to invest in training of the skills to deliver next-generation drug development, toxicology and regenerative medicine (advanced therapeutic medicine product, ATMP) solutions in the form of NATs demonstrates UK need in this growth area. The CDT is timely as it is not just the science that needs to be developed, but the whole NAT ecosystem - science, manufacture, regulation, policy and communication. Thus, the CDT model of producing a connected community of skilled field leaders is required to facilitate UK economic growth in the sector.Our stakeholder partners and industry club have agreed to help us deliver the training needed to achieve our goals. Their willingness, again, demonstrates the need for our graduates in the sector. This CDT's training will address all aspects of priority area 7 - 'Engineering for the Bioeconomy'. Specifically, we will: (1) Deliver training that is developed in collaboration with and is relevant to industry. - We align to the needs of the sector by working with our industrial partners from the biomaterials, cell manufacture, contract research organisation and Pharma sectors.(2) Facilitate multidisciplinary engineering and physical sciences training to enable students to exploit the emerging opportunities.- We build in multidisciplinarity through our supervisor pool who have backgrounds ranging from bioengineering, cell engineering, on-chip technology, physics, electronic engineering, -omic technologies, life sciences, clinical sciences, regenerative medicine and manufacturing; the cohort community will share this multidisciplinarity. Each student will have a physical science, a biomedical science and a stakeholder supervisor, again reinforcing multidisciplinarity.(3) Address key challenges associated with medicines manufacturing.- We will address medicines manufacturing challenges through stakeholder involvement from Pharma and CROs active in drug screening including Astra Zeneca, Charles River Laboratories, Cyprotex, LGC, Nissan Chemical, Reprocell, Sygnature Discovery and Tianjin.(4) Embed creative approaches to product scale-up and process development.- We will embed these approaches through close working with partners including the Centre for Process Innovation, the Cell and Gene Therapy Catapult and industrial partners delivering NATs to the marketplace e.g. Cytochroma, InSphero and OxSyBio.(5) Ensure students develop an understanding of responsible research and innovation (RRI), data issues, health economics, regulatory issues, and user-engagement strategies.- To ensure students develop an understanding of RRI, data issues, economics, regulatory issues and user-engagement strategies we have developed our professional skills training with the Entrepreneur Business School to deliver economics and entrepreneurship, use of TERRAIN for RRI, links to NC3Rs, SNBTS and MHRA to help with regulation training and involvement of the stakeholder partners as a whole to help with user-engagement.The statistics produced by Pharma, UKRI and industry, along with our stakeholder willingness to engage with the CDT provides ample proof of need in the sector for highly skilled graduates. Our training has been tailored to deliver these graduates and build an inclusive, cohesive community with well-developed science, professional and RRI skills.[1] https://goo.gl/qNMTTD[2] https://goo.gl/J9u9eQ